OncoMatch/Clinical Trials/NCT06402708
Postoperative Adjuvant Chemotherapy for Thymic Cancer (FUSCC-Thymic 3)
Is NCT06402708 recruiting? Yes, currently enrolling (Jun 2026). This Phase 3 trial studies Chemotherapy for thymic carcinoma.
Treatment: Chemotherapy — The goal of this clinical trial is to learn the role of adjuvant chemotherapy for patients with thymic carcinoma and completed resection. The main questions it aims to answer are: 1. Does adjuvant chemotherapy decrease disease progression? 2. Does medium dose of three drugs (paclitaxel, cisplatin, 5-FU) well tolerance? Researchers will compare chemoradiotherapy to radiotherapy to see whether chemoradiotherapy could decrease disease progression or not. Participants will: 1. Take radiotherapy (50Gy/25f) with or without 4 cycles of chemotherapy (TPF). 2. Follow up every 3 months in the first two year, and then every 6 months.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Disease stage
Required: Stage I, II, III
Demographics
Lab requirements
Blood counts
White blood cells ≥ 3 × 10^9/L; Neutrophils ≥ 1.5 × 10^9/L; Hemoglobin ≥ 10 g/dL; Platelets ≥ 100 × 10^9/L
Kidney function
Creatinine ≤ 1.5 times the upper limit of normal value
Liver function
Total bilirubin ≤ 1.5 times the upper limit of normal value; AST (SGOT)/ALT (SGPT) ≤ 2.5 times the upper limit of normal value
Cardiac function
No severe heart dysfunction; Symptomatic coronary heart disease and left heart failure excluded
No severe hematopoietic function, heart, lung, liver, kidney dysfunction, or immune deficiency; White blood cells ≥ 3 × 10^9/L; Neutrophils ≥ 1.5 × 10^9/L; Hemoglobin ≥ 10 g/dL; Platelets ≥ 100 × 10^9/L; Total bilirubin ≤ 1.5 times the upper limit of normal value; AST (SGOT)/ALT (SGPT) ≤ 2.5 times the upper limit of normal value; Creatinine ≤ 1.5 times the upper limit of normal value
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06402708 currently recruiting?
Yes, this trial is currently recruiting patients.
What disease stage is eligible?
Stage I or II or III is required.
Is there an age limit?
Yes. Patients must be 75 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify